These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3489577)

  • 1. Pulmonary disease and antipyrine clearance.
    Laybourn C; Tønnesen P; Loft S; Sonne J; Døssing M
    Clin Pharmacol Ther; 1986 Oct; 40(4):415-9. PubMed ID: 3489577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of prednisolone on antipyrine elimination in patients with obstructive lung disease.
    Loft S; Simonsen K; Evald T; Christensen HR; Sonne J; Døssing M
    Eur J Clin Pharmacol; 1987; 33(1):89-91. PubMed ID: 3691602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy.
    Harman AW; Penhall RK; Priestly BG; Frewin DB; Phillips PJ; Clarkson AR
    Aust N Z J Med; 1977 Aug; 7(4):385-90. PubMed ID: 270989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipyrine elimination and hepatic microsomal enzyme activity in patients with liver disease.
    Wensing G; Ohnhaus EE; Hoensch HP
    Clin Pharmacol Ther; 1990 Jun; 47(6):698-705. PubMed ID: 2113450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation of microsomal mixed function oxidase(s) and human lung cancer.
    Kellermann G; Jett JR; Luyten-Kellermann M; Moses HL; Fontana RS
    Cancer; 1980 Mar; 45(6):1438-42. PubMed ID: 7357525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short term anti-tubercular drug therapy and hepatic microsomal enzyme activity. Antipyrine metabolism as an index.
    Hamide A; Sivagnanam G; Raveendran R; Adithan C; Sivaraman V; Chandrasekar S
    J Assoc Physicians India; 1990 Sep; 38(9):631-2. PubMed ID: 2266077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of famotidine, a new H2 receptor antagonist, on antipyrine clearance in healthy volunteers.
    Piersimoni F; Del Prete U; Jèzèquel AM; Orlandi F
    Pharmacol Res Commun; 1987 Feb; 19(2):183-90. PubMed ID: 3588653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction.
    Hepner GW; Vesell ES
    Am J Dig Dis; 1975 Jan; 20(1):9-12. PubMed ID: 1115054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of the functional status of hepatic microsomal enzymes in workers exposed to carbon dioxide and vinyl chloride by using the antipyrine test].
    Lutz W; Stankiewicz A; Krajewska B
    Med Pr; 1987; 38(3):157-66. PubMed ID: 3118136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple method for determination of antipyrine clearance.
    Døssing M; Poulsen HE; Andreasen PB; Tygstrup N
    Clin Pharmacol Ther; 1982 Sep; 32(3):392-6. PubMed ID: 7105629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver failure and drug metabolism.
    Andreasen PB; Ranek L
    Scand J Gastroenterol; 1975; 10(3):293-7. PubMed ID: 1138332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of chronic oral cimetidine on apparent liver blood flow and hepatic microsomal enzyme activity in man.
    Daneshmend TK; Ene MD; Parker G; Roberts CJ
    Gut; 1984 Feb; 25(2):125-8. PubMed ID: 6693040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
    von Mandach U; Jost G; Preisig R
    Schweiz Med Wochenschr; 1985 May; 115(19):651-8. PubMed ID: 3923620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme induction and renal function in man.
    Ohnhaus EE; Martin J; Kinser J; Colombo JP
    Br J Clin Pharmacol; 1977 Feb; 4(1):33-7. PubMed ID: 843422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory action of cimetidine on antipyrine metabolism.
    Piekoszewski W; Rutkowska A; Brandys J
    Pol J Pharmacol; 1993; 45(4):421-9. PubMed ID: 8118484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy and clinical utility of simplified tests of antipyrine metabolism.
    Farrell GC; Zaluzny L
    Br J Clin Pharmacol; 1984 Oct; 18(4):559-65. PubMed ID: 6487495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipyrine kinetics in liver disease and liver transplantation.
    Mehta MU; Venkataramanan R; Burckart GJ; Ptachcinski RJ; Yang SL; Gray JA; Van Thiel DH; Starzl TE
    Clin Pharmacol Ther; 1986 Apr; 39(4):372-7. PubMed ID: 3514052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effect of isoniazid on antipyrine clearance in man.
    Grech-Belanger O; Belanger PM; Lachance J
    J Clin Pharmacol; 1983; 23(11-12):540-4. PubMed ID: 6662978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.